J&J announces positive data from the SPARTAN trial of apalutamide (ARN-509)

We understand that Janssen Biotech has, earlier today, submitted a New Drug Application to the US Food & Drug Administration for the approval of apalutamide (formerly ARN-509) in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

J&J expects to file for approval to market two new prostate cancer drugs

An announcement from Johnson & Johnson yesterday said that the company is projecting filings with regulatory authorities for approval of two new drugs for the treatment of advanced prostate cancer between 2017 and 2021. … READ MORE …

Data from a Phase II trial of ARN-509 (apalutamide) and more

A report posted on line in European Urology has provided us with important clinical data related to the potential of this investigational drug in the treatment of advanced prostate cancer. … READ MORE …

Whatever happened to ARN-509?

Back in June 2013, Johnson & Johnson acquired Aragon Pharmaceuticals and the investigational agent ARN-509 — a potential “precursor” to abiraterone acetate (see below). … READ MORE …

Johnson & Johnson to acquire Aragon Pharmaceuticals

According to a media release issued by the company earlier today, Johnson & Johnson has made a definitive agreement to acquire Aragon Pharmaceuticals, Inc., including all rights to Aragon’s androgen receptor antagonist program. … READ MORE …

New data on new and newer drugs at the GU Cancers meeting

A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …

Preliminary results of a Phase II trial of ARN-509 in CRPC

We have previously discussed the early development of ARN-509 as a novel, second-generation, antiandrogenic agent for the potential treatment of men with advanced prostate cancer. … READ MORE …